These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 31210291)
1. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer. Gong YB; Zou YF Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291 [TBL] [Abstract][Full Text] [Related]
2. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. Dou Q; Xu Y; Zhu Y; Hu Y; Yan Y; Yan H Eur J Pharmacol; 2019 Jun; 852():134-141. PubMed ID: 30831080 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of LncRNA FAM83H-AS1 in hepatocellular carcinoma promotes cell proliferation, migration and invasion by Wnt/β-catenin pathway. Ma YK; Shen TH; Yang XY Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7855-7862. PubMed ID: 31599410 [TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer. Yuan X; Huang Y; Guo M; Hu X; Li P J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565 [TBL] [Abstract][Full Text] [Related]
5. KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer. Ma SY; Wei P; Qu F Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4629-4641. PubMed ID: 31210304 [TBL] [Abstract][Full Text] [Related]
6. The Long Non-Coding RNA (lncRNA) AGAP2-AS1 is Upregulated in Ovarian Carcinoma and Negatively Regulates lncRNA MEG3. Chen J; Peng X; Dai Y Med Sci Monit; 2019 Jun; 25():4699-4704. PubMed ID: 31233485 [TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA ZEB2-AS1 expression is associated with disease progression and predicts outcome in gastric cancer patients. Xu C; Cui H; Li H; Wu Y; An H; Guo C J BUON; 2019; 24(2):663-671. PubMed ID: 31128021 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. Zeng S; Liu S; Feng J; Gao J; Xue F Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Zhang J; Feng S; Su W; Bai S; Xiao L; Wang L; Thomas DG; Lin J; Reddy RM; Carrott PW; Lynch WR; Chang AC; Beer DG; Guo YM; Chen G Sci Rep; 2017 Feb; 7():42819. PubMed ID: 28198463 [TBL] [Abstract][Full Text] [Related]
10. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. Han C; Fu Y; Zeng N; Yin J; Li Q Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085 [TBL] [Abstract][Full Text] [Related]
11. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis. Xu H; Wang L; Jiang X Mol Cell Biochem; 2021 Feb; 476(2):1051-1061. PubMed ID: 33170430 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA ZEB1-AS1 is associated with poor prognosis in gastric cancer and promotes cancer cell metastasis. Liu XJ; Li SL; Li JS; Lu H; Yin LL; Zheng WF; Wang WC Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2624-2630. PubMed ID: 29771411 [TBL] [Abstract][Full Text] [Related]
13. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway. Zhang Y; Dun Y; Zhou S; Huang XH Biomed Pharmacother; 2017 Dec; 96():1216-1221. PubMed ID: 29239819 [TBL] [Abstract][Full Text] [Related]
14. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer. Shan H; Yang Y; Zhu X; Han X; Zhang P; Zhang X J Cell Biochem; 2019 Mar; 120(3):4687-4693. PubMed ID: 30537032 [TBL] [Abstract][Full Text] [Related]
15. lncRNA CDKN2A-AS1 facilitates tumorigenesis and progression of epithelial ovarian cancer via modulating the SOSTDC1-mediated BMP-SMAD signaling pathway. Zhao Q; Dong D; Chu H; Man L; Huang X; Yin L; Zhao D; Mu L; Gao C; Che J; Liu Q Cell Cycle; 2021 Jun; 20(12):1147-1162. PubMed ID: 34110955 [TBL] [Abstract][Full Text] [Related]
16. LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. Wu W; Gao H; Li X; Zhu Y; Peng S; Yu J; Zhan G; Wang J; Liu N; Guo X Cancer Sci; 2019 May; 110(5):1587-1598. PubMed ID: 30941821 [TBL] [Abstract][Full Text] [Related]
17. Expression of long non-coding RNA ZEB1-AS1 in esophageal squamous cell carcinoma and its correlation with tumor progression and patient survival. Wang YL; Bai Y; Yao WJ; Guo L; Wang ZM Int J Clin Exp Pathol; 2015; 8(9):11871-6. PubMed ID: 26617942 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer. Li AH; Zhang HH Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5618-5623. PubMed ID: 29271994 [TBL] [Abstract][Full Text] [Related]
19. Regulations of Exosomal-Transmitted Zhou F; Xu X; Wei W; Chen X; Sun L Discov Med; 2023 Oct; 35(178):877-886. PubMed ID: 37811626 [TBL] [Abstract][Full Text] [Related]
20. LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway. Tuo Z; Zhang J; Xue W Biochem Biophys Res Commun; 2018 May; 499(4):875-881. PubMed ID: 29625110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]